Type II Extension of Indication Application is supported by data from PAPILLON, the first randomised Phase 3 study to read…
Theralase®'s Latest Preclinical Data Supports Combining Immunotherapy Drugs with Theralase® PDCs for Increased Cancer DestructionTORONTO, ON / ACCESSWIRE / October…
Vaccine Stimulates the Body’s Macrophages, Engulfing and Killing Gram Positive/Negative Bacteria, and FungiVaccine provides protection against infections within 24hours and…
JUPITER, Fla., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI),…
mRNA-1083 showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile, compared to licensed standalone vaccinesCompany…
The Recent Acquisition of a Majority Stake in a Manufacturer of Antibacterial and Antiviral Fabrics Expected to Create Synergies for…
Multi-year collaboration utilizes Verily’s Wastewater program to detect the spread of pathogens, including SARS-CoV-2 and MPXVSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Verily,…
TOFIDENCE (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the United StatesFDA approval is based on a…
CAMBRIDGE, MA / ACCESSWIRE / September 29, 2023 / Moderna, Inc. (NASDAQ:MRNA) has become aware that TRC Capital Investment Corporation…
JUPITER, Fla., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology…